EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development

Meir Bialer iD, Svein I Johannessen iD, Matthias J Koepp iD, Emilio Perucca iD, Piero Perucca iD, Torbjörn Tomson iD, H Steve White iD

Epilepsia · 2024-10 · 65 (10) · 2858-2882

DOI: 10.1111/epi.18075 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Epilepsia, online erschienen am 22.08.2024. Verfasst von Meir Bialer und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute for Drug Research, Faculty of Medicine and David R. Bloom Center for Pharmacy, School of Pharmacy, Hebrew University of Jerusalem, Jerusale…. Hauptthemen laut MEDLINE: Anticonvulsants, Epilepsy, Seizures. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 60 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The 17th Eilat Conference on New Antiepileptic Drugs and Devices took place in Madrid, Spain on May 5–8, 2024. As usual, the core part of the conference consisted of presentations on investigational drugs at various stages of development for epilepsy‐related indications. Summaries of information on compounds in preclinical or early clinical development are included in an accompanying publication (Part I). In this article, we provide summaries for five compounds in more advanced clinical development, i.e. compounds for which some information on antiseizure activity in individuals with epilepsy is available. These investigational treatments include azetukalner (XEN1101), a potent, K V 7.2/7.3‐specific potassium channel opener in development for the treatment of focal seizures, generalized tonic–clonic seizures, and major depressive disorder; bexicaserin (LP352), a selective 5‐HT 2C receptor superagonist in development for the treatment of seizures associated with developmental and epileptic encephalopathies; radiprodil, a selective negative allosteric modulator of NR2B subunit‐containing N‐methyl‐D‐aspartate glutamate receptors, in development for the treatment of seizures and behavior manifestations associated with disorders caused by gain‐of‐function mutations in the GRIN1 , −2A , ‐2B , or ‐2D genes; soticlestat (TAK‐935), a selective inhibitor of cholesterol 24‐hydroxylase in development for the treatment of seizures associated with Dravet syndrome and Lennox–Gastaut syndrome; and STK‐001, an antisense oligonucleotide designed to upregulate Na v 1.1 protein expression and improve outcomes in individuals with Dravet syndrome. The diversity in mechanisms of action of these agents illustrates different approaches being pursued in the discovery of novel treatments for seizures and epilepsy. For two of the compounds discussed in this report (azetukalner and soticlestat), clinical evidence of efficacy has already been obtained in a randomized placebo‐controlled adjunctive‐therapy trial. For the other compounds, adequately powered placebo‐controlled efficacy trials have not been completed to date.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AnticonvulsantsEpilepsySeizuresHumansDrug DevelopmentDrugs, InvestigationalAnimals

Stichwörter der Autor:innen

STK‐001antiseizure medicationsazetukalner (XEN1101)bexicaserin (LP352)drug developmentepilepsyradiprodilsoticlestat (TAK‐935)

Substanzen

AnticonvulsantsDrugs, Investigational

Autor:innen und Institutionen

  • Institute for Drug Research, Faculty of Medicine and David R. Bloom Center for Pharmacy, School of Pharmacy, Hebrew University of Jerusalem, Jerusalem, Israel.
  • National Center for Epilepsy, Sandvika, Norway.
  • Oslo University Hospital, member of the European Reference Network EpiCare, Oslo, Norway.
  • Section for Clinical Pharmacology, Department of Pharmacology, Oslo University Hospital, Oslo, Norway.
  • Department of Clinical and Experimental Epilepsy, University College London Queen Square Institute of Neurology, London, UK.
  • Department of Medicine (Austin Health), University of Melbourne, Melbourne, Victoria, Australia.

ORCID-Profile: Meir Bialer, Svein I Johannessen, Matthias J Koepp, Emilio Perucca, Piero Perucca, Torbjörn Tomson, H Steve White

Zitieren

APA

Bialer, M., Johannessen, S. I., Koepp, M. J., Perucca, E., Perucca, P., Tomson, T., & White, H. S. (2024). Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development. Epilepsia, 65(10), 2858-2882. https://doi.org/10.1111/epi.18075

Vancouver

Bialer M, Johannessen SI, Koepp MJ, Perucca E, Perucca P, Tomson T, et al. Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development. Epilepsia. 2024;65(10):2858-2882. doi:10.1111/epi.18075

BibTeX
@article{Bialer2024,
  author = {Bialer, Meir and Johannessen, Svein I and Koepp, Matthias J and Perucca, Emilio and Perucca, Piero and Tomson, Torbjörn and White, H Steve},
  title = {Progress report on new medications for seizures and epilepsy: A summary of the 17th Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XVII). II. Drugs in more advanced clinical development},
  journal = {Epilepsia},
  year = {2024},
  volume = {65},
  number = {10},
  pages = {2858--2882},
  doi = {10.1111/epi.18075}
}
Kostenlos starten →